Medical Oncology Hematology Consultants PA Trials

Medical Oncology Hematology Consultants PA	Welcome, Profile Billing Logout

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Contact, Site Public

NCT05976321: A Study of TAK-279 in Adults With or Without Liver Damage

Recruiting

TAK-279

Takeda

Hepatic Impairment, Healthy Volunteers

08/24

MT-0169-001, NCT04017130: A Study of MT-0169 in Participants With Relapsed or Refractory Multiple Myeloma

Terminated

MT-0169

Molecular Templates, Inc.

Relapsed and/or Refractory Multiple Myeloma

12/23

NCT05976334: An Absorption, Distribution, Metabolism, Excretion (ADME) Study of [14C]Subasumstat in Adults With Advanced or Metastatic Solid Tumors

Recruiting

Europe

[14C] Subasumstat, TAK-981, Subasumstat

Takeda

Solid Tumors

08/24

04/25

NCT06377228: A Study of TAK-007 in Adults With Refractory Lupus Nephritis (LN)

Not yet recruiting

TAK-007, Chemotherapy Agents

Takeda

Refractory Lupus Nephritis

04/29

NCT06111547: A Study of TAK-279 in Healthy Chinese Adults

Recruiting

RoW

TAK-279, Placebo

Takeda

Healthy Volunteers

12/24

NCT05992155: A Study of TAK-279 in Adults With or Without Kidney Problems

Completed

TAK-279

Takeda

Renal Impairment, Healthy Volunteers

05/24

NCT05891158: A Study About Fazirsiran in People With and Without Liver Problems

Recruiting

Europe

Fazirsiran, TAK-999

Takeda

Hepatic Impairment

04/25

iinnovate-2, NCT05556616: A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma

Active, not recruiting

120

Europe, US, RoW

Modakafusp alfa, TAK-573, Lenalidomide, Bortezomib, Carfilzomib, Daratumumab, Pomalidomide

Takeda

Multiple Myeloma

01/24

06/24

NCT05702424: Evaluation of IGM-7354 in Adults With Relapsed and/or Refractory Cancer

Active, not recruiting

IGM-7354

IGM Biosciences, Inc.

Solid Tumor

02/26

03/26

NCT05174221: A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy

Active, not recruiting

Europe, Japan, US, RoW

Mezagitamab, TAK-079

Takeda

Kidney Disease, Glomerulonephritis

03/26

NCT04506619 / 2020-002726-84: Safety and Efficacy Outcomes Following Previously Administered Short-Term Treatment With SHP607 in Extremely Premature Infants

Terminated

N/A

Europe, US

No Intervention

Oak Hill Bio Ltd

Retinopathy of Prematurity (ROP), Intraventricular Hemorrhage, Bronchopulmonary Dysplasia, Chronic Lung Disease of Prematurity

08/22

EXTRACT, NCT05207423: A Chart Review Study of Adults With Advanced NSCLC

Completed

N/A

179

Europe, Canada, RoW

Takeda

Non-small Cell Lung Cancer (NSCLC)

02/23

INTUITION-CPF, NCT04844593: A Study Using Artificial Intelligence to Identify Adults With Complex Perianal Fistulas Associated With Crohn's Disease

Completed

N/A

Europe

Takeda

Crohn Disease, Rectal Fistula

02/23

04/24

NCT05795361: Post-trial Access Program of Idursulfase-IT Along With Elaprase in Children With Hunter Syndrome

Available

N/A

Europe, US, RoW

Idursulfase-IT, HGT-2310, TAK-609

Takeda

Hunter Syndrome

NCT05265078: A Study on Estimated Risks of Certain Adverse Events in Adults With Von Willebrand Disease (VWD) Treated With Veyvondi

Completed

N/A

102

Europe

Takeda

Von Willebrand Disease (VWD)

04/23

DOrianT, NCT04659798: A Study to Investigate the Relationship Between Duration of Treatment and Response in Patients With Multiple Myeloma (MM) or Systemic AL Amyloidosis Treated in Real-life Practice

Completed

N/A

240

Europe

Takeda

Multiple Myeloma, Immunoglobulin Light-chain Amyloidosis

04/23

08/23

NCT04877431: A Study of Teduglutide (Revestive®) in Children, Teenagers and Adults With Short Bowel Disease

Completed

N/A

RoW

Takeda

Short Bowel Syndrome

06/23

NCT04583007: Expanded Access for the Prevention of Acute Attacks of 1) Hereditary Angioedema (HAE) in Children and 2) Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) in Teenagers and Adults

No Longer Available

N/A

Europe, Canada, US

Lanadelumab 150 mg, TAK-743, SHP643, DX-2930, Lanadelumab 300 mg

Shire, Takeda Development Center Americas, Inc.

Hereditary Angioedema (HAE), Angioedema

TAK-743-4008, NCT04955964: A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE) in Argentina

Completed

N/A

RoW

Takeda

Angioedemas, Hereditary

08/23

ermEX-20, NCT05419700: A Spanish Medical Record Review of Clinical Characteristics and Outcomes in Non-small Cell Lung Cancer Participants With EGFR Exon 20 Insertion

Completed

N/A

Europe

Takeda

Non-small Cell Lung Cancer (NSCLC)

09/23

NCT05695560: A Survey to Describe the Experience and Unmet Needs of Persons Living With Von Willebrand Disease (VWD) and Their Caregivers

Completed

N/A

Canada

No Intervention

Takeda

Von Willebrand Disease (VWD)

11/23

REALM, NCT05506774: A Study of People With CD30 Positive Lymphoma in China

Active, not recruiting

N/A

2800

RoW

Takeda

Lymphoma

12/24

NCT05489640: A Study in Adults With Hereditary Angioedema (HAE) Who Currently Receive Icatibant at Home

Recruiting

N/A

100

Europe

No Intervention

Takeda

Hereditary Angioedema (HAE)

06/24

PROSPECT, NCT05578417: A Study to Review the Treatment and Outcomes of Teenagers and Adults With Non-histaminergic Angioedema With Normal C1 Inhibitor in Canada

Recruiting

N/A

150

Canada

No Intervention

Takeda

Hereditary Angioedema (HAE), Angioedema

03/24

06/24

NCT03824522: Post Marketing Surveillance Study for ADYNOVATE in South Korea

Completed

N/A

341

RoW

ADYNOVATE, PEGylated rFVIII

Takeda, Takeda Pharma Korea Co. Ltd.

Hemophilia A

01/24

NCT04885920: A Study on Administration Choices of Vedolizumab and Outcomes for Adults With Inflammatory Bowel Disease (IBD) (VARIETY - CROATIA AND SLOVENIA)

Completed

N/A

120

Europe, RoW

Takeda

Inflammatory Bowel Diseases, Crohns Disease, Colitis, Ulcerative

03/24

CREDIT, NCT05288491: A Study of Chinese Adults With Lymphoma

Recruiting

N/A

1000

RoW

Takeda

Lymphoma

06/24

NCT05371028: A Study of Teduglutide (Revestive®) in Participants With Short Bowel Syndrome (SBS) in Canada

Recruiting

N/A

100

Canada

Non-interventional Study

Takeda

Short Bowel Syndrome (SBS)

07/24

NCT05106764: Early Detection of Fabry Disease

Active, not recruiting

N/A

Europe

No intervention

Takeda

Fabry Disease

04/24

NCT04861233: A Study of Lubiprostone to Treat Constipation

Recruiting

N/A

3000

RoW

No Intervention

Jeil Pharmaceutical Co., Ltd.

Constipation

05/24

11/24

NCT04872491: A Study of Vedolizumab in Adults in Real-World Practice

Active, not recruiting

N/A

500

RoW

Takeda

Colitis, Ulcerative, Crohn Disease

07/24

DRALEGA, NCT05982717: A Study to Gather Information About Overall Occurrence and New Cases of Dravet and Lennox-Gastaut Syndromes in Children, Teenagers and Adults in Spain

Recruiting

N/A

250

Europe

No intervention

Takeda

Dravet Syndrome (DS), Lennox-Gastaut Syndrome (LGS)

05/24

NCT04840680: A Study of Real-World Use of Ixazomib Citrate in People With Multiple Myeloma (MM)

Recruiting

N/A

165

RoW

No Intervention

Takeda

Multiple Myeloma

06/24

NCT05886478: A Study in Adults With Cutaneous T-cell Lymphoma (CTCL) Retreated With Brentuximab Vedotin

Recruiting

N/A

Europe

No intervention

Takeda

T-Cell Lymphoma

06/24

mECHromatic, NCT05755568: A Study to Learn About Metachromatic Leukodystrophy (MLD) in Children in Spain

Withdrawn

N/A

Europe

No Intervention

Takeda

Metachromatic Leukodystrophy (MLD)

07/24

NCT06346899: A Study of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) in Persons With HAE in China

Not yet recruiting

N/A

130

RoW

No intervention

Takeda

Hereditary Angioedema (HAE)

08/25

ENABLE, NCT04130191: A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II

Active, not recruiting

N/A

140

Europe, RoW

Shire, Takeda Development Center Americas, Inc.

Hereditary Angioedema (HAE)

09/24

LANDSCAPE, NCT04943796: A Study to Learn About the Occurrence of ADHD in Adults With Mental Conditions and Their Quality of Life

Recruiting

N/A

576

Europe, Canada

Takeda

Attention Deficit Hyperactivity Disorder (ADHD)

09/24

INFINITE, NCT04328662: A Study of Ninlaro in Real World Clinical Practice in China

Recruiting

N/A

3000

RoW

Takeda

Multiple Myeloma, Neoplasms, Plasma Cell

09/25

NCT06104878: A Study in Adults With Advanced Classical Hodgkin's Lymphoma (cHL) in Brazil Treated With Brentuximab Vedotin Together With Chemotherapy Compared to Chemotherapy Alone

Withdrawn

N/A

200

RoW

No Intervention

Takeda

Hodgkin Lymphoma

10/24

ELEGANT, NCT05737849: A Study to Learn About the Tests Looking for a Gene Mutation in Adults With Lung Cancer in China

Withdrawn

N/A

10800

RoW

No Intervention

Takeda

Non-small Cell Lung Cancer (NSCLC)

12/24

NCT04837222: A Study of Brentuximab Vedotin in Adults With CD30-positive Lymphoma

Recruiting

N/A

1000

RoW

No Intervention

Takeda

Lymphoma

01/25

SUNRISE, NCT05192863: A Study of Vedolizumab in Adults With Crohn's Disease (CD)

Active, not recruiting

N/A

Europe, Canada, RoW

No Intervention

Takeda

Crohn's Disease

01/25

PEDS, NCT04721366: A Study of Velaglucerase Alfa (VPRIV) Given as Standard Patient Care in Young Children With Gaucher Disease

Completed

N/A

Standard of Care, SOC

Takeda

Gaucher Disease

04/23

NCT05626088: A Study in Adults With Inflammatory Bowel Disease (IBD) Receiving Vedolizumab in the Patient Support Program (PSP) in Brazil

Recruiting

N/A

2160

RoW

No Intervention

Takeda

Ulcerative Colitis, Crohn's Disease

01/25

HyMMy, NCT05879757: Real-world Usage of HyQvia in Multiple Myeloma Adults With Secondary Immunodeficiency

Recruiting

N/A

100

Europe, RoW

No Intervention

Takeda

Multiple Myeloma, Secondary Immunodeficiency (SID)

07/25

03/26

LEADER, NCT04985643: A Study of Real Life Treatment for Multiple Myeloma (MM)

Recruiting

N/A

111

RoW

Takeda

Multiple Myeloma

08/25

VARIETY, NCT05384080: A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Practice in Poland

Active, not recruiting

N/A

165

Europe

Takeda

Inflammatory Bowel Disease (IBD), Crohn's Disease, Ulcerative Colitis

08/25

NCT05013190: A Study of NINLARO® in Chinese Adults With Multiple Myeloma

Recruiting

N/A

320

RoW

No intervention

Takeda

Multiple Myeloma

10/25

NCT04961840: A Study to Assess Maternal and Fetal Outcomes After Taking Prucalopride During Pregnancy

Active, not recruiting

N/A

100

No Intervention

Takeda

Constipation, Pregnancy

12/25

NCT04799496: A Study of Kynteles Injection (Vedolizumab) in Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease or Chronic Pouchitis

Recruiting

N/A

600

RoW

Takeda

Inflammatory Bowel Diseases, Colitis, Ulcerative, Crohn Disease

01/26

CHOPIN, NCT05147181: A Study With Lanadelumab in Persons With Hereditary Angioedema (HAE) in Poland

Recruiting

N/A

Europe

Takeda

Hereditary Angioedema (HAE)

03/26

NCT04869280: Post-Marketing Study of Prucalopride Safety In Pregnancy

Recruiting

N/A

616

No Intervention

Takeda, The Organization of Teratology Information Specialists

Chronic Idiopathic Constipation (CIC)

05/26

BV-MAZOVIA, NCT05100056: A Study of Brentuximab Vedotin in Adults With Hodgkin's Lymphoma

Recruiting

N/A

Europe

No Intervention

Takeda

Hodgkin Lymphoma

06/26

NCT04838522: A Study of Prucalopride in Breastfeeding Women With Constipation

Recruiting

N/A

No Intervention

Takeda, UC San Diego Human Milk Research Biorepository

Chronic Idiopathic Constipation (CIC)

12/26

NCT01034969: Firazyr® Patient Registry (Icatibant Outcome Survey - IOS)

Recruiting

N/A

3000

Europe, RoW

Shire, Takeda Development Center Americas, Inc.

Hereditary Angioedema (HAE)

01/27

ENTIRETY, NCT05735327: A Study of Brigatinib as Preferred First Therapy for Adults With Non-Small Cell Lung Cancer (NSCLC)

Recruiting

N/A

Europe

No intervention

Takeda

Non-small Cell Lung Cancer (NSCLC)

06/27

NCT05428345: A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea

Recruiting

N/A

600

RoW

Takeda

Ulcerative Colitis, Crohn's Disease, Inflammatory Bowel Disease (IBD)

11/27

NCT04158934: A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A

Active, not recruiting

N/A

207

Europe, US, RoW

ADYNOVI/ADYNOVATE, Antihaemophilic Factor [Recombinant] PEGylated rurioctocog alfa pegol, TAK-660, BAX 855

Baxalta now part of Shire

Hemophilia A

02/30

PARADIGHM, NCT01922440: A Registry for Participants With Chronic Hypoparathyroidism

Active, not recruiting

N/A

1340

Europe, Canada, US

No intervention

Takeda, Takeda Development Center Americas, Inc.

Hypoparathyroidism

11/34

Cusnir, Mike

VERACITY, NCT04844749: Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent

Terminated

105

VERU-111, Sabizabulin, Enzalutamide, Abiraterone, XTANDI, Zytiga

Veru Inc.

Metastatic Castration-resistant Prostate Cancer, Androgen Resistant Prostatic Cancer

05/23

PANOVA-3, NCT03377491: Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel

Active, not recruiting

556

Europe, Canada, US, RoW

NovoTTF-200T, TTFields, Gemcitabine, nab paclitaxel

NovoCure Ltd.

Pancreas Adenocarcinoma

09/24

10/24

MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting

400

Europe, Canada, Japan, US, RoW

tucatinib, TUKYSA, ONT-380, ARRY-380, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil

Seagen Inc., Merck Sharp & Dohme LLC

Colorectal Neoplasms

08/25

04/28

FIRST-308, NCT05948475: Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma

Recruiting

200

Europe, US, RoW

Tinengotinib 8 mg, Tinengotinib 10 mg, Physician's Choice

TransThera Sciences (Nanjing), Inc.

Cholangiocarcinoma

05/26

08/26

DORA, NCT03574571: A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer

Recruiting

738

Europe, US, RoW

Docetaxel 75 mg/m2, Docetaxel 60 mg/m2, Radium-223

Memorial Sloan Kettering Cancer Center, Bayer

Prostate Cancer

06/26

GRANITE, NCT05141721: A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer

Active, not recruiting

2/3

700

GRT-C901, GRT-R902, Atezolizumab, Tecentriq, Ipilimumab, Yervoy, Fluoropyrimidine plus leucovorin, Xeloda, Bevacizumab, Avastin

Gritstone bio, Inc.

Colorectal Neoplasms

03/27

STIMVAX, NCT04444622: Immunotherapy for Third Line Metastatic Colorectal Cancer

Recruiting

AlloStim, StimVax

Immunovative Therapies, Ltd., Mirror Biologics, Inc.

Metastatic Colorectal Cancer

11/24

04/25

NCT04919642: Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma

Completed

TT-00420

TransThera Sciences (Nanjing), Inc.

Cholangiocarcinoma, FGFR2 Fusion, FGFR2 Gene Mutation, FGFR1 Alteration, FGFR3 Alteration

02/24

NCT04169347: FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer

Active, not recruiting

Oxaliplatin, Irinotecan, Leucovorin, Panitumumab

Criterium, Inc., Amgen

Colorectal Cancer Metastatic

12/24

01/25

NCT05945823: Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

Recruiting

Europe, US

Futibatinib, TAS-120, Pembrolizumab, MK-3475, KEYTRUDA®, Cisplatin, PLATINOL®, 5-FU, ADRUCIL®, Oxaliplatin, ELOXATIN®, Leucovorin, calcium folinate, folinic acid, WELLCOVORIN®, Levoleucovorin, calcium levofolinate, levofolinic acid, FUSILEV®, Irinotecan

Taiho Oncology, Inc.

Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Cancer, Siewert Type 1 GEJ Cancer, Pancreatic Cancer

01/25

05/25

1-BETTER, NCT04825288: XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer

Active, not recruiting

1/2

XB2001 or Placebo

XBiotech, Inc.

Pancreatic Cancer

02/24

05/24

KEYNOTE-E58, NCT04041310: Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors

Recruiting

1/2

115

Europe, Canada, US

GAd-209-FSP low dose, MVA-209-FSP low dose, GAd-209-FSP high dose, MVA-209-FSP high dose, GAd20-209-FSP, RP2D, MVA-209-FSP, RP2D, KEYTRUDA®, pembrolizumab

Nouscom SRL, Merck Sharp & Dohme LLC

Solid Tumor, Adult

03/25

07/26

NCT04507503: Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

Approved for marketing

N/A

TAS-120, Futibatinib

Taiho Oncology, Inc.

Advanced Cholangiocarcinoma

MRD, NCT05210283: CORRECT Study of Minimal Residual Disease Detection in Colorectal Cancer

Recruiting

N/A

750

Canada, US

MRD

Exact Sciences Corporation, NSABP Foundation Inc

Colorectal Cancer

02/28

Leal, Alexis D

NCT04963283: Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer

Active, not recruiting

Cabozantinib, Cabometyx, Nivolumab, Opdivo

University of Colorado, Denver, National Cancer Institute (NCI), Criterium, Inc., Bristol-Myers Squibb, Exelixis

Colorectal Adenocarcinoma, Colon Cancer, Colon Adenocarcinoma, Rectum Cancer, Rectal Cancer, Rectal Adenocarcinoma, Colorectal Cancer

02/25

02/26

AMPLIFY-7P, NCT05726864: A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors

Recruiting

1/2

156

ELI-002 7P

Elicio Therapeutics

Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, KRAS G12D, KRAS G12R, KRAS G12V, KRAS G12A, KRAS G12C, KRAS G12S, KRAS G13D, NRAS G12D, NRAS G12R, NRAS G12V, NRAS G12C, NRAS G12S

11/26

AMPLIFY-201, NCT04853017: A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors

Active, not recruiting

ELI-002 2P

Elicio Therapeutics

Minimal Residual Disease, KRAS G12D, KRAS G12R, NRAS G12D, NRAS G12R, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Non-small Cell Lung Cancer, Ovarian Cancer, Cholangiocarcinoma, Bile Duct Cancer, Gallbladder Carcinoma

01/23

03/26

NCT06028373: A Study of ATG-031 in Advanced Solid Tumors or B-cell Non-Hodgkin Lymphomas

Recruiting

ATG-031

Antengene Biologics Limited

Advanced Solid Tumors, B-cell Non-Hodgkin Lymphomas

12/25

06/26

Amini, Arya

NCT05085496: Radiotherapy in Combination With Atezolizumab in Locally Advanced Borderline Resectable or Unresectable Cutaneous SCC

Recruiting

Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Stereotactic Body Radiation Therapy, SABR, SBRT, Stereotactic Ablative Body Radiation Therapy

City of Hope Medical Center, Genentech, Inc., National Cancer Institute (NCI)

Locally Advanced Skin Squamous Cell Carcinoma, Resectable Skin Squamous Cell Carcinoma, Unresectable Skin Squamous Cell Carcinoma

12/24

Rangaswami, Arun A

ARYA-2, NCT04634357: ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma

Recruiting

1/2

ET140203 T Cells

Eureka Therapeutics Inc.

Hepatoblastoma, Hepatocellular Carcinoma (HCC), Liver Neoplasms, Metastatic Liver Cancer, Liver Cancer, HEMNOS

01/26

01/28

Bobolis, Kristie A

A011801, NCT04457596: T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

Jan 2028 - Dec 2028: From CompassHER2 RD trial in combination with Kadcyla for HER2+ breast cancer

Recruiting

1031

Canada, US

Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment

Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Seagen Inc.

Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Synchronous Bilateral Breast Carcinoma

01/28

05/35

Schallenkamp, John M

UP-NEXT, NCT05329545: Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer

Terminated

Canada, US, RoW

Upifitimab rilsodotin, XMT-1536 Antibody Drug Conjugate, Placebo

Mersana Therapeutics, GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT)

High Grade Serous Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer

09/23

SWOG S2302, NCT05633602: Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

Recruiting

700

Chemotherapy, Chemo, Chemotherapy (NOS), Chemotherapy, Cancer, General, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Ramucirumab, Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B, Cyramza, IMC-1121B, LY3009806

SWOG Cancer Research Network, National Cancer Institute (NCI), Eli Lilly and Company, Merck Sharp & Dohme LLC

Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8

03/25

03/28

A011801, NCT04457596: T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

Jan 2028 - Dec 2028: From CompassHER2 RD trial in combination with Kadcyla for HER2+ breast cancer

Recruiting

1031

Canada, US

Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment

Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Seagen Inc.

01/28

05/35

DRAMMATIC, NCT04071457: S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

Jan 2023 - Jun 2023 : From trial for patients with r/r multiple myeloma treated with an IMiD and PI

Recruiting

1100

Canada, US

Lenalidomide, CC-5013, Revlimid, Daratumumab/rHuPH20

SWOG Cancer Research Network, National Cancer Institute (NCI), Janssen, LP

Multiple Myeloma

07/29

07/40

CIRCULATE-US, NCT05174169: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

Recruiting

2/3

1912

Canada, US

Signatera test, mFOLFOX6 3-6 month, CAPOX 3 month, mFOLFIRINOX, mFOLFOX6 6 month, CAPOX 6 month

NRG Oncology, Natera, Inc., National Cancer Institute (NCI)

Stage III Colon Cancer

03/29

03/30

A071401, NCT02523014: Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

Recruiting

124

Vismodegib, GDC-0449, FAK Inhibitor GSK2256098, Capivasertib, AZD5363, Abemaciclib

Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), GlaxoSmithKline, Genentech, Inc., Brain Science Foundation

Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation

10/24

NCT03994796: Genetic Testing in Guiding Treatment for Patients With Brain Metastases

Recruiting

186

Abemaciclib, PI3K Inhibitor paxalisib, Entrectinib, Adagrasib, MRTX849

Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Mirati Therapeutics Inc., Genentech, Inc., Eli Lilly and Company, Kazia Therapeutics Limited

CDK Gene Mutation, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, NTRK Family Gene Mutation, PI3K Gene Mutation, ROS1 Gene Mutation, KRAS G12C Mutation

10/24

06/25

NCT04647916: Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases

Recruiting

Sacituzumab Govitecan, hRS7-SN38 Antibody Drug Conjugate, IMMU-132, RS7-SN38, Sacituzumab Govitecan-hziy, Trodelvy

SWOG Cancer Research Network, National Cancer Institute (NCI), Gilead Sciences

Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic HER2 Negative Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Prognostic Stage IV Breast Cancer AJCC v8

02/25

12/26

Siddique, Shahzad

A011801, NCT04457596: T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

Jan 2028 - Dec 2028: From CompassHER2 RD trial in combination with Kadcyla for HER2+ breast cancer

Recruiting

1031

Canada, US

Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment

Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Seagen Inc.

01/28

05/35

DRAMMATIC, NCT04071457: S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

Jan 2023 - Jun 2023 : From trial for patients with r/r multiple myeloma treated with an IMiD and PI

Recruiting

1100

Canada, US

Lenalidomide, CC-5013, Revlimid, Daratumumab/rHuPH20

SWOG Cancer Research Network, National Cancer Institute (NCI), Janssen, LP

Multiple Myeloma

07/29

07/40

CIRCULATE-US, NCT05174169: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

Recruiting

2/3

1912

Canada, US

Signatera test, mFOLFOX6 3-6 month, CAPOX 3 month, mFOLFIRINOX, mFOLFOX6 6 month, CAPOX 6 month

NRG Oncology, Natera, Inc., National Cancer Institute (NCI)

Stage III Colon Cancer

03/29

03/30

A071401, NCT02523014: Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

Recruiting

124

Vismodegib, GDC-0449, FAK Inhibitor GSK2256098, Capivasertib, AZD5363, Abemaciclib

Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), GlaxoSmithKline, Genentech, Inc., Brain Science Foundation

Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation

10/24

NCT03994796: Genetic Testing in Guiding Treatment for Patients With Brain Metastases

Recruiting

186

Abemaciclib, PI3K Inhibitor paxalisib, Entrectinib, Adagrasib, MRTX849

Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Mirati Therapeutics Inc., Genentech, Inc., Eli Lilly and Company, Kazia Therapeutics Limited

CDK Gene Mutation, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, NTRK Family Gene Mutation, PI3K Gene Mutation, ROS1 Gene Mutation, KRAS G12C Mutation

10/24

06/25

Quigley, John G

NCT03258931: Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML

Recruiting

510

Crenolanib, Crenolanib besylate, Midostaurin, Cytarabine, Duanorubicin

Arog Pharmaceuticals, Inc.

Newly Diagnosed FLT3 Mutated AML

11/22

11/24

SELECT MDS-1, NCT04797780 / 2020-004528-40: Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome

Recruiting

550

Europe, Canada, US, RoW

Tamibarotene, SY-1425, Placebo, Azacitidine

Syros Pharmaceuticals

Myelodysplastic Syndromes

11/24

02/29

NCT04070768: Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113

Active, not recruiting

Gemtuzumab Ozogamicin, GO, Venetoclax

John Quigley, Pfizer, AbbVie

Acute Myeloid Leukemia

10/23

10/24

Urquhart, Alexander T

A011801, NCT04457596: T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

Jan 2028 - Dec 2028: From CompassHER2 RD trial in combination with Kadcyla for HER2+ breast cancer

Recruiting

1031

Canada, US

Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment

Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Seagen Inc.

01/28

05/35

Aziz, Ashraf R

NCT05028348 / 2021-001691-41: A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma

	Jul 2024 - Dec 2024: Top-line data from XPORT-MM-031 trial in combination with pomalidomide and dexamethasone for multiple myeloma
	Jun 2023 - Dec 2023: Completion of enrolment of trial in combination with pomalidomide and dexamethasone for multiple myeloma

Recruiting

222

Europe, US

Selinexor, KPT-330, Elotuzumab, Pomalidomide, Dexamethasone Oral

European Myeloma Network, Karyopharm Therapeutics Inc

Multiple Myeloma

03/26

03/29

ASC4START, NCT05456191: A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)

Recruiting

550

Europe, Canada, US, RoW

Asciminib, ABL001, Nilotinib

Novartis Pharmaceuticals

Philadelphia Chromosome-Positive Chronic Myeloid Leukemia

02/27

03/27



	Diseases Companies Products Productz Mechanisms of Action Sites